Table 1.
Method | Effectiveness (%) | Side effect |
AZA to 6-MP | 48-73[45-48] | Nausea, vomiting, hepatotoxicity, neutropenia, pancreatitis |
6-MP to AZA | Not effective[48,50,51] | Nausea, vomiting, hepatotoxicity, neutropenia, pancreatitis |
Desensitization | 25[51] | Hypersensitivity reaction |
Combination infliximab/thiopurine | 25[72,74] | Lymphoma, infection |
6-TG | 46-82[50,58] | NRH, veno-occlusive disease and possible tumor |
Allopurinol supplementation | 25-75[68,69] | Skin rash, renal impairment, leukopenia |
Split-dosing | 60[75] | Reduces 6-MP, AZA associated adverse effects |
AZA: Azathioprine; 6-MP: 6-mercaptopurine; NRH: Nodular regenerative hyperplasia; 6-TG: 6-thioguanine.